NASDAQ:PRE

Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture "Insighta" for Breakthrough Multi-Cancer Early Detection Screening

Retrieved on: 
星期一, 六月 26, 2023
ACT, Faculty, DNA, Commercialization, Communications and Information Technology Commission (Saudi Arabia), UBS AG, Workflow, Survival, Holy Grail, Liquid biopsy, Clinical trial, Cancer, Liver, Global health, Innovation, Genomics, Chinese University of Hong Kong, Mother, Science, University of Hong Kong, Plasma, Death, Chinese, University of Toronto Faculty of Medicine, Royal Medal, CUHK, UBS, Ageing, Lasker, Research, Health, Royal Society, NIPT, Dean (education), Cryptocurrency, Video game, Film industry, Pharmaceutical industry, Vaccine, Cirina, Illumina, Medicine

-- Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo.

Key Points: 
  • -- Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo.
  • -- By 2030, the early cancer detection screening opportunity is estimated to be US$6bn in Asia on an annual basis.
  • The joint venture will be governed by a six-person board of directors composed of three directors from each side, with Prof.
  • From prevention (CircleDNA) and early detection (Insighta) to treatment (ACT), our innovative approach promises to significantly raise the bar in healthcare."

Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results, New Business Strategy Focused on Precision Oncology

Retrieved on: 
星期二, 三月 14, 2023
ACT, AstraZeneca, Cancer, Acquisition, United Kingdom, Workforce, Medicine, Chairperson, Genomics, Chinese University of Hong Kong, Chinese, Patient, Nature, Investment, EBITDA, COVID-19, FDA, Communication, Growth, Coronavirus Scientific Advisory Board, Social responsibility, Cryptocurrency, Pharmaceutical industry, Medical imaging, Vaccine, Renewable energy, Video game, Insurance, Bank, Artisan

-- Cash and other short-term assets of US$242.1 million as of December 31, 2022

Key Points: 
  • -- Cash and other short-term assets of US$242.1 million as of December 31, 2022
    -- Embarked on a new business strategy focused on precision oncology, as the Company exits the COVID-19 testing business.
  • Furthermore, I am immensely optimistic with our new business strategy in precision oncology.
  • Prenetics is focusing its business strategy to genomics and precision oncology, and is dedicated to transforming patients' care through advanced genomic and molecular technologies.
  • -- Adjusted EBITDA was US$12.1 million for the fourth quarter 2022 compared to US$(5.9) million for the fourth quarter 2021.

Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology

Retrieved on: 
星期六, 三月 4, 2023

The SAB includes a diverse group of highly respected experts in oncology and genomics, each with unique expertise and backgrounds in the field of precision oncology.

Key Points: 
  • The SAB includes a diverse group of highly respected experts in oncology and genomics, each with unique expertise and backgrounds in the field of precision oncology.
  • "We are honoured to have these accomplished scientific thought-leaders join Prenetics' SAB," said Danny Yeung, CEO and Co-Founder of Prenetics.
  • "Their insights and experience will be an invaluable asset to fuel our innovative solutions in the field of precision oncology.
  • Precision oncology is a rapidly evolving field, and I believe that Prenetics is well-positioned to make a significant impact in this area.